Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: SOF/VEL and SOF/VEL/VOX
Tig


Admin

Status: Offline
Posts: 7950
Date:
RE: SOF/VEL and SOF/VEL/VOX
Permalink  
 


Section title changed per your request! Let me know if it is listed according to your wishes.



__________________

Tig

61 yo GT1A - 5 Mil - A2/F3 - (1996) Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 1-4 years!

Hep C FAQ

Signature Line Set Up/Abbreviations   Payment Assistance

 



Guru

Status: Offline
Posts: 2394
Date:
RE: GT 3's and SOF/VEL trials
Permalink  
 


More old stuff - on SOF/VEL/VOX:

Wish I knew how to change the title of this thread to just "SOF/VEL and SOF/VEL/VOX" info, as it has morphed from beyond where it started - we've gone from trials only (for difficult GT's like 3's), to now prescriptions of SOF/VEL starting to be made available for every GT! (Near regardless to cirrhosis, genotyping, or existing RAV identification!) And, SOF/VEL may soon be joined by VOX (NS3/4A) - for Gilead's triplet for just about any relapser as a rescue regime!  

regist2.virology-education.com/2016/12co...ion/21_Sulkowski.pdf

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Geyawd! Another exhaustively complete one on sof/vel (I should say so! at 60 pages)! Near everything in one nutshell tho ...

http://www.gilead.ca/pdf/ca/Epclusa_pm_english.pdf

Hmmm - maybe this thread title should change, as it has morphed beyond just sof/vel trials for GT 3's, and is on to sof/vel and vox info applying to all GT's!

 

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 552
Date:
Permalink  
 

Hi Pablo,

thanks for the succinct summary. This woman is just too smart for me. I try to start reading, concentrating really hard, screwing my mouth into what I hope is an intelligently following along expression, nodding wisely periodically but then.... I realise for the last five minutes my eyes have been dutifully scanning the words but my brain has been thinking about feeding the dog or my itchy armpit. 

confuse

Syd

ps. Love you Canuck and appreciate all the info you find for us. Xxxx 



__________________

Contracted Hep C 1969. Genome Type 2, treatment naive. Began 12 week RIBA/sof/Dac on 12/11/15. Cirrhosis. VL before treatment 4m. Treatment extended another 12 weeks without Riba. No virus detected at 9 weeks.



Senior Member

Status: Offline
Posts: 362
Date:
Permalink  
 

Great stuff Canuck.  I think it's safe to say that if one can get prescribed sof/vel/vox, especially so for 12 weeks (instead of 8), you have the best chance of SVR compared to another other regime regardless of your genotype, prior treatment status and cirrhosis level.

 



__________________

44 y.o. male, HCV G4 since 1996, F-scan score 9, F2, Failed prior I/R, finished sof/vel/vox 8 weeks 5/16, pre-treatment VL 2 million, EOT UND, EOT+4 UND, EOT+12 UND.



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

 

One of the earlier (phase 2) sof/vel/vox trials - comparing to sof/vel/vox to sof/vel/riba

When are they going to start using vox versus riba for a triple? We have relapaser's of other DAA's and folk with particularly well suited RAV's waiting!!

download this slide kit - HCV-Trials.com

www.hcv-trials.com/studies/TRILOGY-3/TRILOGY-3.pptx
SOF/VEL/GS-9857: 400/100/100 mg FDC qd. Lawitz E, EASL 2016, Abs. PS021, J Hepatol 2016;64:S146. Design.TRILOGY-3 Study: SOF/VEL/GS-9857 RBV...
 
 
Even though this earlier trial result is now "old", as we wait for further data updates on phase 3 results's - note the "sides" - (Vox triple compared to the riba triple) - we see "less"/different adverse side effects, none of riba's blood dyscrasia's. Aside from adverse effects, just based on effectiveness of the sof/vel/vox triple alone (gleaned from other reports) I believe that vox as an added NS3/4A for a sof/vel triple is superior over riba in multiple/different and important ways.
 
Further (on Lawitz's data):
 

HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 IN PREVIOUSLY TREATED PATIENTS WITH HCV GENOTYPES 1 THROUGH 6

Dr Eric Lawitz presented results from 3 phase 2 trials that evaluated the combination of sofosbuvir, velpatasvir, and GS-9857 (VOX) in patients with previously treated HCV.1-8 Velpatasvir is an NS5A inhibitor, and GS-9857 is an NS3/4A inhibitor with a superior resistance profile compared with other NS3 protease inhibitors. All 3 DAAs have demonstrated efficacy against HCV genotypes 1 through 6. The single-center, open-label, phase 2 TRILOGY-3 trial enrolled patients with HCV genotype 1 infection previously treated for at least 6 weeks with a DAA.The study design designated enrollment of approximately 50% of patients with compensated cirrhosis. Patients were stratified based on cirrhosis status and prior treatment with NS5A inhibitors. Twenty-four patients received a single daily tablet of sofosbuvir (400 mg)/velpatasvir (100 mg), plus daily GS-9857 (100 mg) for 12 weeks. In 25 patients, this regimen was administered with the addition of weight-based ribavirin. The primary endpoint was SVR12.

Patients had a mean age of 54 years (range, 18-75 years), and approximately two-thirds were male. Approximately 86% of patients had the IL28B non-CC genotype. As planned, half of patients had cirrhosis. The mean level of HCV RNA was 6.3 log10 IU/mL (range, 5.2-7.1 log10 IU/mL). Eighty-eight percent of patients had HCV genotype 1a infection. Previous treatment included an NS5A inhibitor in 41%. Among these patients, 6% had received only the NS5A inhibitor, 14% had also received an NS3 inhibitor, and 20% had received prior treatment with an NS5A inhibitor, an NS5B inhibitor, and an NS3 inhibitor. Among patients who had not received an NS5A inhibitor, prior treatments included an NS3 inhibitor (31%), an NS5B inhibitor (16%), and both (12%).

The overall SVR12 rate was 98%. One patient in the ribavirin-containing arm experienced virologic failure at follow-up week 4. The patient who relapsed was a 61-year-old black man with cirrhosis, who had previously received treatment with ledipasvir/sofosbuvir for 24 weeks. He relapsed after discontinuation of therapy. Baseline analysis for the TRILOGY-3 study showed that this patient had NS5A resistance-associated variants (RAVs), but no NS3 or NS5B RAVs. After relapsing during the follow-up period, the patient was found to have 1 additional NS5A RAV and 4 new NS3 RAVs. In the entire study population, 36 patients (75%) had baseline RAVs. Fifteen percent had NS5A RAVs only, 29% had NS3 RAVs only, and 31% had multiple-class RAVs. Among the 36 patients with any baseline RAVs, 35 (97%) achieved SVR12 (Figure 4). All 12 of the patients who lacked baseline RAVs achieved SVR12.

AEs were common but generally mild-to-moderate in severity. AEs of any grade were reported in 11 patients (46%) in the ribavirin-free arm and in 15 patients (60%) in the ribavirin-containing arm. In the ribavirin-containing arm, there was a single grade 3 AE, consisting of rash that resolved upon discontinuation of ribavirin. There were no permanent treatment discontinuations or deaths during the study. One serious AE of pneumonia occurred in the ribavirin-free arm; however, this patient completed the 12 weeks of DAA treatment and achieved SVR12. Grade 3/4 laboratory abnormalities were more common in patients who received ribavirin (24% vs 4%). Hemoglobin levels of less than 10 g/dL were observed in 6 patients (24%) in the ribavirin arm vs none in the ribavirin-free arm. The most common AEs of any grade in the ribavirin arm were fatigue (36%), anemia (16%), and diarrhea (13%). These AEs did not occur in the ribavirin-free arm.

Dr Lawitz also presented results for treatment-experienced patients enrolled in 2 phase 2 trials that investigated treatment with sofosbuvir, velpatasvir, and GS-9857.10 Study GS-US-367-1168 included 197 patients with HCV genotype 1 infection; study GS-US-367-1169 included 128 patients with HCV genotype 2 to 6. Both trials included patients with or without cirrhosis, as well as patients who had received prior HCV treatment, including DAAs. Patients with HCV genotype 1 had received prior treatment with an NS5A inhibitor or at least 2 DAAs from different classes. Patients with genotypes 2 through 6 had received prior treatment with pegylated interferon plus ribavirin or any DAA. The 2 studies enrolled a total of 128 treatment-experienced patients, all of whom received 12 weeks of treatment with daily sofosbuvir (400 mg)/velpatasvir (100 mg) plus daily GS-9857 (100 mg).

The 128 patients had a mean age of 58 years (range, 37-77 years), 75% were male, and 82% were white. Approximately three-fourths of patients had the IL28B non-CC genotype, and 48% had cirrhosis. The mean HCV RNA level was 6.3 log10 IU/mL (range, 3.8-8.1 log10IU/mL). Patients had HCV genotypes 1 (49%), 2 (16%), 3 (27%), and 4 or 6 (7%). Prior DAA treatments included 1 DAA class in 28% and 2 or more DAA classes in 51%, and 27% of patients had received prior treatment with an NS5A inhibitor. Twenty-one percent of patients had received prior treatment with pegylated interferon plus ribavirin but no prior DAA treatment. Among the 66 patients (52%) with prior non-NS5A DAA treatment, 24% had received prior treatment with an NS5B inhibitor alone. Another 24% had received treatment with an NS5B inhibitor and an NS3 inhibitor. The remaining 4% of patients had received treatment with an NS3 inhibitor, an NS5B nucleotide polymerase inhibitor, and/or an NS5B nonnucleotide polymerase inhibitor. Among the 35 patients (27%) who had received prior treatment with an NS5A inhibitor, 11% had received prior treatment with an NS3 inhibitor and an NS5A inhibitor, with other combinations accounting for the remaining patients, including
1 patient who had failed all 4 classes
of DAAs.

At baseline, 77 patients (60%) had RAVs, and 76 of these patients (99%) achieved SVR12. The 1 patient who failed to achieve SVR12 was infected with HCV genotype 3 and relapsed at follow-up week 8. Among the 51 patients (40%) without baseline RAVs, 51 (100%) achieved SVR12. Among the 77 patients with baseline RAVs, 76 achieved SVR12 (99%; Figure 5). In the entire study group, SVR12 was reported in 100% of patients with HCV genotype 1, 2, 4, or 6 and in 97% of patients with HCV genotype 3. Subgroup analysis showed that the presence or absence of cirrhosis did not affect the likelihood of achieving SVR12. Similarly, prior treatment had no apparent impact on the likelihood of achieving SVR12. The single patient who experienced virologic failure had HCV genotype 3, was cirrhotic, had no prior NS5A exposure, and had been exposed to 1 class of DAA therapy prior to study enrollment.

Sixty-five percent of patients experienced an AE of any grade. Two patients (2%) experienced a grade 3 AE, and 2 patients (2%) experienced a serious AE. One patient (<1%) discontinued treatment due to an AE considered unrelated to study treatment, and 1 patient (<1%) died from a presumed sudden cardiac arrest 14 weeks after completing the study. Eleven patients (9%) had grade 3/4 laboratory abnormalities without clinical consequences. The most common AEs were headache (22%), diarrhea (19%), fatigue (20%), and nausea (14%).

 


-- Edited by Canuck on Saturday 17th of September 2016 05:38:24 PM

__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Still not much data out there about that NS3/4A "VOX" yet (as far as it starting to be used along with sof/vel, versus just the folks getting it via trials), but, here is some more about it's "interactions": 

B. DRUG INTERACTIONS
 
1. DDI with Voxilaprevir (GS-9857)

 
SOF/Velpatasvir/Voxilaprevir (VOX) is a three-drug fixed dose DAA combination being evaluated in Phase 3 trials. In vitro, VOX is a substrate for CYP3A4, CYP2C8, the OATP uptake transporters and the efflux transporters P-gp and BCRP. VOX is also an inhibitor of P-gp and BCRP in vitro. Dr. Kirby presented drug interaction studies with VOX (Abstracts #O_24 and #O_25). Tables below show results of VEL as a victim and perpetrator in interactions. Results indicate VOX is very sensitive to hepatic inhibition of OATP transporters, so coadministration of VOX with potent OATP inhibitors is not recommended.
 
Inhibitors of CYP3A4, CYP2C8, and P-gp are likely okay with VOX. As with all HCV treatments, interactions with HMG-CoA reductase inhibitors (statins) must be considered with a potential need to change statins or use a reduced dose of the statin. It is likely based on these data that VOX will have problematic interactions with efavirenz and HIV protease inhibitors.
 
http://regist2.virology-education.com/2016/17HIVHEPPK/40_Kirby.pdf
 

voxPerp



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

2 WEEK PCR's

A study, and then a doc's comment at bottom, reflecting on any importance attached to a 2 week PCRs data in older regime(s) study: (Another feather in the cap alluded to for the new world of sof/vel!)

Clinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimens.

Maasoumy B., et al.
J Hepatology 2016 ; April 13 (Epub ahead of print)

Background & Aims : EASL guidelines recommend HCV-RNA measurements at specific time-points during sofosbuvir(SOF)-therapy. However, it remains unclear, how these results should be interpreted. We aimed to analyse whether on-treatment HCV-RNA levels predict relapse comparing the CobasAmpliPrep/CobasTaqMan v2.0 (CAP/CTM) and Abbott RealTime HCV (ART) assays.

Methods : Samples were collected from 298 patients(HCV-genotypes; GT1-5) at weeks(w) 0, 1, 2, 4, 8, 12, 16, 20 and 24 during SOF-based therapy at two University clinics and tested for HCV-RNA level by CAP/CTM and ART. Patients were treated with SOF/ribavirin(RBV) 12/24w (n=99), pegylated-interferon-alfa(Peg-IFN)/SOF/RBV 12w (n=51), SOF/simeprevir(SMV)±RBV 12w (n=69) or SOF/daclatasvir±RBV 12/24w (n=79).

Results : HCV-RNA levels during the first 4 weeks of SOF/RBV-therapy were significantly lower in GT3-patients who achieved SVR compared with those who relapsed. All GT3-patients with a week 2 result <45IU/ml by CAP/CTM achieved SVR but only 33% of those with >45IU/ml(p=0.0003). Similar results were documented with ART and 60IU/ml as cut-off (SVR:100% vs. 29%;p=0.0002). In contrast, HCV-RNA levels during early treatment phases were not significantly related to relapse in patients treated with other SOF-based regimens. Residual HCV-RNA was frequently detected by ART at later stages of therapy. However, SVR-rates remained high in these patients. At the end of SOF/SMV±RBV6 therapy HCV-RNA was detectable with ART in 20% of patients, of whom 92% achieved SVR.

Conclusions : HCV-RNA levels assessed at week 2 of SOF/RBV-therapy can predict relapse in GT3-patients. Detectable HCV-RNA results at later stages during SOF-based therapy may occur frequently with the more sensitive ART. However, this should not lead to treatment extension.

Expert's Commentary

The practical impact of this paper is not marginal. For years we have been using on- treatment viral kinetics to individualize IFN-based treatment duration for our chronic HCV infected patients. Now, with the use of Direct Antiviral Agents the meaning of this predictor can be considered insignificant. The only exception seems to be presented in this study identifying, in patients with genotype 3 infection a week 2 HCV RNA >45 IU/ml by Cobas Ampli Prep/CobaseTaqMan or >60 IU/ml by Abbott Real Time, as predictive of relapse. This result appears of immediate utility, although with the arrival of new and more potent combinations for treatment of genotype 3 patients, such as the combination of velpatasvir and sofosbuvir, the week 2 prediction can be expected to be less relevant. Interestingly, the study clarifies also the issue of a residual viremia at the end of treatment. Until now no systematic evaluation of this observed phenomenon was available. Detectable HCV RNA below the quantification threshold, at the end of the established treatment duration can be observed in up to 20% of patients receiving oral antivirals. According to the study results, we should not consider a residual viremia as predictive of relapse. As shown in this study, in 92% of subjects this residual HCV RNA was not followed by a relapse and should not generate attempts to extend treatment duration.

Alessandra Mangia, San Giovanni Rotondo, Italy

 

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Yawn. Ho-hum. Here's some already stale "stock" talk ... still no new riveting new news on VOX!  Mildly interesting tho - SOF/VEL patent to 2032, as is the "guess" that VOX and VEL really were created "in-house", and that sof/vel is a good buy for countries 'cause they will save a bundle, because of no GT'ing required? And, just when is this triplet VOX "salvage" thing ever going to be rolled-out?

For hepatitis C

1. Sofosbuvir/velpatasvir (SOF/VEL)

This has a patent expiry of 2032 for both the US and EU.

I look at this as a breakthrough, first-in-class product that may be receiving insufficient attention from analysts. It has a PDUFA date of June 28. The cure rates even for genotypes that are notoriously difficult to treat, such as genotype 3, are impressive (95%).

In addition to being first-in-class, perhaps time will also show it to be best in class.

GILD's main speaker at the Merrill Lynch conference, EVP Paul Carter, volunteered that this is going to be a very important product for developing countries, most notably China. His comments indicated that GILD is hard at work getting SOF/VEL to the Chinese market ASAP.

The benefit of SOF/VEL is that once HCV is found to be chronically infecting a patient who will benefit from cure, nearly everyone can just take one pill a day for 12 weeks with a high chance of cure. This is going to be transformative for parts of the world with limited scientific and/or financial resources, as patients can be treated with no genotyping needed.

Also, within the developed world, certain important genotypes (mainly types 2 and 3) will be treated with SOF/VEL rather than (usually) Sovaldi and accompanying drug(s). Whether this replacement of Sovaldi by SOF/VEL will have much economic benefit to GILD is unclear.

However, maybe a marketing benefit could be bundling SOF/VEL with anything ranging from access, or preferred access as appropriate, to Harvoni and/or SOF/VEL for genotypes 1 and 4. It's these genotypes where the real competition with AbbVie's and Merck's (NYSE:MRK) products occurs. In return, a lower price on SOF/VEL could be offered.

In any case, the key with this combo is that it opens up vast numbers of patients globally to treatment with a GILD product.

Velpatasvir, the "VEL" in the combo's current name, was developed in-house at GILD to my knowledge.

 

2. SOF/VEL plus voxilaprevir (formerly GS-9857, voxilaprevir is a pan-genotypic protease inhibitor)

Mr. Carter went into the rationale for developing this product. He noted that protease inhibitors are prone to have additional side effects. He offered up the standard GILD points that safety and efficacy, not duration of treatment, is what the regulators care about, and more or less the only things they care about. So, GILD is thinking of this triplet as salvage therapy, for difficult cases, etc., but with potentially shorter treatment courses.

For those keeping score, I do not recall GILD acquiring GS-9857, but I could be wrong. For now I'm thinking of it as yet another anti-viral that has been discovered internally.



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)

Tig


Admin

Status: Offline
Posts: 7950
Date:
Permalink  
 

Good question! That was as clear as mud.... smile



__________________

Tig

61 yo GT1A - 5 Mil - A2/F3 - (1996) Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 1-4 years!

Hep C FAQ

Signature Line Set Up/Abbreviations   Payment Assistance

 



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Oh, for the love of plain English!!

VOX and P450 inhibitors/inducers

http://www.natap.org/2016/Pharm/Pharm_54.htm

Sheesh, grapefruit or NO grapefruit, 'fer pet's sake!  doh C.



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
GT 3's and SOF/VEL trials - and, SOF/VEL/VOX, and Epclusa roll-out (for all GT's 1-6, and "relapse rescue").
Permalink  
 


From hepctip:

Epclusa (sofosbuvir / velpatasvir), the first hepatitis C treatment able to cure six types of the hep C virus with high success rates against all of the six types, has been approved for use in America for all of those six types!

The hep C treatment sofosbuvir / velpatasvir (American brand name Epclusa) was approved by the U.S. Food and Drug Administration (FDA) yesterday. It was approved for the treatment of adult patients with a chronic hepatitis C virus infection, genotype1, 2, 3, 4, 5, or 6. This approval means that it can be prescribed to those with or without liver cirrhosis and can be prescribed with or without the drug ribavirin (prescribed with ribavirin for patients with liver cirrhosis, Child-Pugh B or C).

Sofosbuvir / Velpatasvir (American Brand Name Epclusa)

Description: Sofosbuvir / velpatasvir is a short-course hep C interferon-free treatment that can be prescribed with or without ribavirin. It is a pill taken once a day.

It is the first once daily pill treatment for patients with hep C genotype 2 and 3, without the need for ribavirin.

Approved for in the States: Epclusa taken for 12 weeks was approved in patients without liver cirrhosis or with compensated liver cirrhosis (Child-Pugh A), and in combination with ribavirin (RBV) for patients with more serious  liver cirrhosis (Child-Pugh B or C).

Common Side Effects: The most common side effects of sofosbuvir / velpatasvir are headache and fatigue. However, If it is combined with ribavirin, patients may experience side effects from the ribavirin.

Sofosbuvir / Velpatasvir in Canada

Sofosbuvir / velpatasvir isn't approved for use in Canada yet.

Clinical Trial Results for Sofosbuvir / Velpatasvir

In Phase III clinical trials, the treatment's safety and effectiveness as a 12 week treatment was evaluated on 1,558 patients without liver cirrhosis or with mild cirrhosis. With or without ribavirin, it cured 95-99% of those patients. In trials, it also cured 94% of those with  moderate to severe liver cirrhosis.

 

"This drug regimen changes the standard of care in treating patients with HCV. We can now cure almost everyone with a very simple treatment," said Dr. Jordan Feld, a liver specialist at Toronto Western Hospital.



-- Edited by Canuck on Tuesday 23rd of August 2016 06:24:23 AM

__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)

Tig


Admin

Status: Offline
Posts: 7950
Date:
RE: GT 3's and SOF/VEL trials
Permalink  
 


One thing I don't want is to get into is a political debate. That said, I will say that I wouldn't believe much of what you hear from politicians right now. It's an election year in the USA and if I've learned anything, a politician will promise you a trip to the Moon and end up giving you a ticket for a cab ride to the Dollar store. 

I think one option is in the easy access to certified generic medications. There are things that can be done and Big Pharma gets a lot of R&D subsidies and tax breaks from the US government. They have a right to profits, that's free market capitalism. I think there are limits to the obscene profits when, as we all know, people are sick and dying. We have a big can of worms in front of us and we have to find a way to open it in an orderly fashion. We have enough confusion and hurdles to care...

The goal is



Attachments
__________________

Tig

61 yo GT1A - 5 Mil - A2/F3 - (1996) Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 1-4 years!

Hep C FAQ

Signature Line Set Up/Abbreviations   Payment Assistance

 



Guru

Status: Offline
Posts: 1031
Date:
Permalink  
 

Sure SF...

I can't find the exact article but here is something very similar:

 

http://www.drugchannels.net/2016/08/seven-takeaways-from-new-2017-cvs.html



__________________

Wendy 53 y/o, DX 1994, geno 1A F1

1999 TX 1 - Inter -non responder 2001 TX 2 - Peg + Riba - viral load tripled and taken off

T3:  Harvoni 12 weeks Sept. 19, 2015 ALT 41 AST 30 VL 541800 UND at EOT and SVR 24 ALT 18 AST 26 platelets 223

 



Guru

Status: Offline
Posts: 679
Date:
Permalink  
 

Great post Canuck!

It's good to see that Epclusa is getting on the momentum program and $60,000 at least is going in the right direction.

Lisa

I am glad to see the drug companies being challenged and especially when some tax payer money helped fund them. I wonder how many other countries will not recognize Gilead's patent on their drugs. I realized they need to recoup their R&D money but selling  100 x more drugs at lower costs will still get them there and wipe of the disease.

Wendy,

Is that list available? Could you possibly post a link to it?

Have a great weekend everyone.

 

SF

 

 



__________________

65 yo, GT1A, , Cirrhosis, F-Scan F4 33.5, TX Naive Harvoni 12 wks

SOT 2/9/16 / ALT 187 AST 114 VL 2.3M.    POSTS

EOT 5/2/16  ALT 35/ AST/25  platlets 126 C/B VL UND

EOT +12 7/26/16  ALT 25 /AST 22/ ALP 83  platlets 129 C/B VL UND

EOT + 24 10/18/16 ALT 27/ AST 20/ ALP 71 platlets 153 C UND

 * SVR *



Guru

Status: Offline
Posts: 1031
Date:
Permalink  
 

On a similar note, in our local news today there was an article on which drugs CVS and Express Scripts will not cover in 2017 and many of the HCV treatments were on there but it did list what they are replaced with and they listed many of the new protocols, which I was glad to see. 



__________________

Wendy 53 y/o, DX 1994, geno 1A F1

1999 TX 1 - Inter -non responder 2001 TX 2 - Peg + Riba - viral load tripled and taken off

T3:  Harvoni 12 weeks Sept. 19, 2015 ALT 41 AST 30 VL 541800 UND at EOT and SVR 24 ALT 18 AST 26 platelets 223

 



Guru

Status: Offline
Posts: 893
Date:
Permalink  
 

I was reading yesterday that Hilary Clinton has challenged drug companies over their prices, naming specifically Gilead and their Hep C drugs. Tax payers money help fund their research and they repay us with huge prices on top. These huge profits are stopping a universal cure for a disease that is now effectively is easy to treat and cure. I am pretty happy to hear this is now being targeted. I know there are many countries still not able to access these simple life saving drugs and we are effectively and there is no justification. Lets hope something is done about it now...



__________________

Genotype: 3b

VL.�over 15, 000 000

Failed TX 2014: Interferon/Riba.

Cured using Sof/Dak combination.

I can eat cake again! <3 



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

More about Epclusa (in Canada) for GT 1-6 - hmph, riba reccomendations! - what going to happen to that VOX they trialed?

Here is how Epclusa is meant to be used for different types of HCV-associated liver disease:

  • people who have chronic HCV infection without cirrhosis (severe scarring of the liver) or who have compensated (symptom-free) cirrhosis - one tablet taken once daily with or without food for 12 consecutive weeks
  • people who have chronic HCV infection and symptoms (decompensated) of cirrhosis - one tablet taken once daily with or without food for 12 consecutive weeks. The antiviral drug ribavirin must also be taken. Ribavirin is taken twice daily with food, also for 12 consecutive weeks.

Summary of important safety information

Before starting a new medication, always speak to your doctor, nurse and pharmacist about its potential interactions with other drugs (such as prescribed and over-the-counter medicines, supplements and herbs). These healthcare providers can tell you how to take Epclusa safely.

Here is some limited safety information:

  • The drug amiodarone is used to treat abnormal heart rhythm. Gilead does not recommend that people who are taking amiodarone also take Epclusa, as this can result in reduced heart rhythm (slower rate of heart beats; bradycardia). This can be dangerous. If patients taking amiodarone have no alternative to using Epclusa, Gilead recommends that doctors order cardiac monitoring in people who take these medicines together.
  • Epclusa contains velpatasvir. The HIV drug efavirenz (Sustiva, Stocrin and in Atripla) reduces the amount of velpatasvir in the blood. Therefore, efavirenz users should not take Epclusa.
  • The herb St. John's wort (or its active ingredients hypericin and hyperforin) should not be used with Epclusa, as it can lower levels of both sofosbuvir and velpatasvir.

 

Access to Epclusa - (only in Canada you say??) as usual ... every Province will be different!

After Health Canada licenses a drug, physicians can prescribe it but patients must pay for it themselves unless they have a private insurance plan that covers it. It may take weeks or months for such coverage to take effect after licensure. In the months ahead, Gilead Sciences and provincial and territorial formularies will be negotiating the price of Epclusa ...

... in Canada, provincial and territorial ministries of health heavily subsidize the cost of anti-HCV medications. Each ministry has a listing of drugs for which it is prepared to pay. These listings are called formularies. Formularies can also place restrictions on who can access the drugs they are covering.

... In the months ahead, Gilead Sciences and provincial and territorial formularies will be negotiating the price of Epclusa. Your pharmacist, nurse or doctor can tell you when Epclusa is listed on your region's formulary.

The wholesale cost of Epclusa in Canada is about $60,000 for a 12-week course of therapy. Pharmacies in Canada can anticipate being able to order Epclusa from wholesalers by mid-August 2016.

The pharmaceutical company has stated: "To assist eligible HCV patients in Canada with access to Epclusa, Gilead Canada has added Epclusa to the Gilead Momentum Support Program, which provides information to patients and healthcare providers to help ensure patient access to medication." Patients who may be interested in the use of Epclusa should first speak to their healthcare provider. For more information regarding the Momentum Support Program in Canada, call 1.855.447.7977.

Only in BC you say? Check it out - "approved" does not mean "available", to all people, in every Province. Apparently I could, between Aug 24 and Sep 21 lobby BC Pharmacare to say, "Yes, please - make Epclusa available via Pharmacare in BC" - that doesn't mean that Epclusa would then be available to me or anyone anytime soon! Even today, I (as a "former" GT 3a, I love saying that BTW - "former"!)) I would still not be able to get even Daklinza easily! I have watched Daklinza stalled in BC Pharmacare since at least July of 2015! Good grief,  GT3's still wait (along with all the other 1 thru 6 GT's that Epclusa could be helping today)! Hm, let's hope they work out the MONEY part of our liver problem, sometime soon!

http://www.hepctip.ca/wp-content/uploads/2016/08/August.png



-- Edited by Canuck on Thursday 18th of August 2016 05:47:18 AM

__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 1516
Date:
Permalink  
 

Not to worry Tig,

Yesterday you were only as "Old as Dirt" ...

it's today that you're actually "Older Than Dirt" ... so you got at least a whole day's reprieve there.

 

Dave



__________________

63yy,HCV,2b,F3-A1, Sof/Riba,12wks Tx   SOT: 1/20/16, HCV-RNA 9,816,581, ALT 56, Hb 14.6

4wk: HCV-RNA <15 Detected, ALT 15, AST 17, Hb 13.6 EOT: 4/12/16, ALT 18 , Hb 12.9176a2f85d05d9c965eafe199f2ba9ba5.jpg SVR Achieved 7/8/16

 



Senior Member

Status: Offline
Posts: 261
Date:
Permalink  
 

Happy birthday season Tig.  There's still time for cake, though the bon fire and the ice cream may have messy results.

Just wanted to say, I'm glad you were born.biggrin Really am.



__________________

GT2a, VL 681,500, Less than F1, Treatment Naive

12 wks Sovaldi/Ribavirin, SOT 2/25/16, EOT 5/17/16

UND at 2,4,8 and 12 wks during treatment but ribavirin crazy.

ALT/AST normal EOT

SVR12 8/13/2016!!!!!!!!!  I WON!!

EOT 6 Months 11/12/2016  CURED

 



Senior Member

Status: Offline
Posts: 122
Date:
Permalink  
 

Hey Tig, Happy Birthday,  welcome to the 60 + Club.   Hope you had a great day.   Chris



__________________

F 63,  1b  1974, no cirrhosis, fibro scan 5.8 F0-F1,fibro test .37 ,V/L 702987, ALT 90, AST 75.  ABBVIE Topaz II on 10-30-14 Viekira Pak no RIBA , EOT 1-22-15 SVR, ALT 37, AST 29, 4-15-15 SVR12 - fibro test .22,  1-21-16 SVR 52 ,  1-21-17 SVR 104!



Guru

Status: Offline
Posts: 1031
Date:
Permalink  
 

Happy Birthday Tig

Convention was in my area so just gone for the day/night

 



__________________

Wendy 53 y/o, DX 1994, geno 1A F1

1999 TX 1 - Inter -non responder 2001 TX 2 - Peg + Riba - viral load tripled and taken off

T3:  Harvoni 12 weeks Sept. 19, 2015 ALT 41 AST 30 VL 541800 UND at EOT and SVR 24 ALT 18 AST 26 platelets 223

 

Tig


Admin

Status: Offline
Posts: 7950
Date:
Permalink  
 

"OLDER THAN DIRT"?  Boo Hoo, Hoo.... I'm silently weeping in my bonfire of candles on my non existent cake, lol! I didn't even get a darn cake! I asked for a DQ ice cream cake and the blasted place was out! How dare they! Do they not realize the importance of this day? I hope you will be kind enough to find one and send it. Overnight FedEx and dry ice should do the trick, ha, ha!

Respect and deference is always foremost in my thoughts, especially when it is followed up with a nice DQ Toffee ice cream cake! YUM, YUM, YUM..... biggrin



__________________

Tig

61 yo GT1A - 5 Mil - A2/F3 - (1996) Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 1-4 years!

Hep C FAQ

Signature Line Set Up/Abbreviations   Payment Assistance

 



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Wendy,

Back so soon! Glad it was good.

Are you trying to be nice to TIG because it is his birthday (that's the rumour anyway) and because he is wise, benevolent and older than dirt?

I figured out that that is why you complimented him with that "TYG = Thank you God". hee hee 

Tig, I will have you know I am your senoir and as an elder I expect some respect and deference man. wink hee hee - wheee!



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)

Tig


Admin

Status: Offline
Posts: 7950
Date:
Permalink  
 

Thanks Canuck! LOTS of good information and will be a great resource. That will be a "multi cup" of coffee reading assignment! We are all grateful for your persistence smile 



__________________

Tig

61 yo GT1A - 5 Mil - A2/F3 - (1996) Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 1-4 years!

Hep C FAQ

Signature Line Set Up/Abbreviations   Payment Assistance

 



Guru

Status: Offline
Posts: 1031
Date:
Permalink  
 

Dave you will be pleased to know I did not eat any doughnuts and drank more water than coffee lol. 

Had a great time with my other family. Worked registration, saw lots of old friends and heard 2 great speakers. Canuck, one was from Canada! Saw 2 of my counselors from when I was in treatment 25 years ago. (they all had bets I would never make it) I am beyond blessed to have this community as well as that one in my life. TYG = Thank you God!



__________________

Wendy 53 y/o, DX 1994, geno 1A F1

1999 TX 1 - Inter -non responder 2001 TX 2 - Peg + Riba - viral load tripled and taken off

T3:  Harvoni 12 weeks Sept. 19, 2015 ALT 41 AST 30 VL 541800 UND at EOT and SVR 24 ALT 18 AST 26 platelets 223

 



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Wendy, I've been to 3 different kinds of AA meetings, I did not go exactly for the usual reasons some people might go, but I wanted to go and did, and was warmly welcomed. It was a really good learning thing for me, and an eye opener, a very good positive encounter. I quickly was awed at the depths of us, in all our glory of strengths, sober honesty and humbling weaknesses. I never so quickly bonded, related, cried and laughed with a group of people faster with these 3 different groups who were as diverse as any group can be. I gained immediate respect for people who were struggling and winning. I benefited for it and learned a lot. I was so impressed by this group of people, much like how I am impressed by this group of people. C. 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Hey, 

That link about VOX that I was trying to make work before, NOW, it does work, but, after you click on the link "Journal of Viral Hepatitis" to get to the journal, then you have to scroll down and click on the first "article" listed there (to open it and read it) ... 

Journal of Viral Hepatitis

GS-9857 in Patients With Chronic Hepatitis C Virus Genotype 1-4 Infection

A Randomized, Double-blind, Dose-ranging Phase 1 Study

M. Rodriguez-Torres; S. Glass; J. Hill; B. Freilich; D. Hassman; A. M. Di Bisceglie; J. G. Taylor; B. J. Kirby; H. Dvory-Sobol; J. C. Yang; D. An; L. M. Stamm; D. M. Brainard; S. Kim; D. Krefetz; W. Smith; T. Marbury; E. Lawitz

Disclosures

J Viral Hepat. 2016;23(8):614-622. 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 1516
Date:
Permalink  
 

Have a safe trip and do enjoy the convention Wendy

I'm picturing 748000 gallons of coffee and at least that many donuts on a HUGE table toward the back and a Serenity Prayer that can be heard as far away as Cleveland, OH smile

 

Dave



__________________

63yy,HCV,2b,F3-A1, Sof/Riba,12wks Tx   SOT: 1/20/16, HCV-RNA 9,816,581, ALT 56, Hb 14.6

4wk: HCV-RNA <15 Detected, ALT 15, AST 17, Hb 13.6 EOT: 4/12/16, ALT 18 , Hb 12.9176a2f85d05d9c965eafe199f2ba9ba5.jpg SVR Achieved 7/8/16

 



Senior Member

Status: Offline
Posts: 122
Date:
Permalink  
 

C..... Great Information.  Thank you again for all your research.    CC



__________________

F 63,  1b  1974, no cirrhosis, fibro scan 5.8 F0-F1,fibro test .37 ,V/L 702987, ALT 90, AST 75.  ABBVIE Topaz II on 10-30-14 Viekira Pak no RIBA , EOT 1-22-15 SVR, ALT 37, AST 29, 4-15-15 SVR12 - fibro test .22,  1-21-16 SVR 52 ,  1-21-17 SVR 104!



Guru

Status: Offline
Posts: 1516
Date:
Permalink  
 

Thanks Canuck,

For the new link and the info!

It's appreciated!!

 

Dave



__________________

63yy,HCV,2b,F3-A1, Sof/Riba,12wks Tx   SOT: 1/20/16, HCV-RNA 9,816,581, ALT 56, Hb 14.6

4wk: HCV-RNA <15 Detected, ALT 15, AST 17, Hb 13.6 EOT: 4/12/16, ALT 18 , Hb 12.9176a2f85d05d9c965eafe199f2ba9ba5.jpg SVR Achieved 7/8/16

 



Guru

Status: Offline
Posts: 1031
Date:
Permalink  
 

You did it Canuck! And thank you. You put so much into this (not just this article but in general) for everyone and it is appreciated. 

I started to read it and will have to revisit it. Lots to take in! 

Enjoy your weekend. I am headed to the 60th FL State Convention for AA. (my other family)

 



__________________

Wendy 53 y/o, DX 1994, geno 1A F1

1999 TX 1 - Inter -non responder 2001 TX 2 - Peg + Riba - viral load tripled and taken off

T3:  Harvoni 12 weeks Sept. 19, 2015 ALT 41 AST 30 VL 541800 UND at EOT and SVR 24 ALT 18 AST 26 platelets 223

 



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Soooo, is this link going to work this time I wonder!? All 34 pages of it no less!? I can't seem to get anything to post lately! Just me!

 

 Epclusa - Gilead

Potent Inducers of CYP. 5.3 Risks Associated with Ribavirin and EPCLUSA. Combination Treatment. 6 ADVERSE REACTIONS. 6.1 Clinical Trials Experience.

 

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 1516
Date:
Permalink  
 

Hiya Canuck,

The link wants a sign-in.

Is it possible to quote the article?

Thanks for digging through the data to bring us these helpful morsels. smile

 

Linux



__________________

63yy,HCV,2b,F3-A1, Sof/Riba,12wks Tx   SOT: 1/20/16, HCV-RNA 9,816,581, ALT 56, Hb 14.6

4wk: HCV-RNA <15 Detected, ALT 15, AST 17, Hb 13.6 EOT: 4/12/16, ALT 18 , Hb 12.9176a2f85d05d9c965eafe199f2ba9ba5.jpg SVR Achieved 7/8/16

 



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Finally! A wee bit more about the NS3/4A, "Vox", that I and Pablito consumed, along with our 8 weeks of sof/vel (Epculsa)! And which webtomass also consumed along with his 12 weeks of sof/vel. Nothing too earth shattering/riveting here, but, at least they are starting to publish some data about "vox"! smile

Edited: There was personally identifiable info in that link. Medscape articles post better if you can find or post in PDF.

Whal-dern-it all. Infuriating this! Don't know HOW to do stuff on computer!! Quite a few times I can't post things no matter how much I fash around with them, photos/PDF's are the worst! hmmph. I just have NO aptitude for learning computer stuff I am afraid. Try this? - it is the title and place the thing lives ...

Journal of Viral Hepatitis

GS-9857 in Patients With Chronic Hepatitis C Virus Genotype 1-4 Infection

A Randomized, Double-blind, Dose-ranging Phase 1 Study

M. Rodriguez-Torres; S. Glass; J. Hill; B. Freilich; D. Hassman; A. M. Di Bisceglie; J. G. Taylor; B. J. Kirby; H. Dvory-Sobol; J. C. Yang; D. An; L. M. Stamm; D. M. Brainard; S. Kim; D. Krefetz; W. Smith; T. Marbury; E. Lawitz

Disclosures

J Viral Hepat. 2016;23(8):614-622. 

I also found a "contraindications thing" about Epclusa (mild routine stuff info) but cannot post it!! Tried and tried. Drat. It's in a photo, or A/V, or slide/PDF form of some sort of animal which the computerially challenged would NEVER know how to manage moving it! Duh, no can do! dohbleh C.



-- Edited by Tig56 on Friday 5th of August 2016 09:53:05 PM



-- Edited by Canuck on Saturday 6th of August 2016 01:06:16 AM

__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 552
Date:
Permalink  
 

Thanks for all your work for us, Canuck.

Syd

 



__________________

Contracted Hep C 1969. Genome Type 2, treatment naive. Began 12 week RIBA/sof/Dac on 12/11/15. Cirrhosis. VL before treatment 4m. Treatment extended another 12 weeks without Riba. No virus detected at 9 weeks.



Senior Member

Status: Offline
Posts: 362
Date:
Permalink  
 

Very interesting but what about patents?  



__________________

44 y.o. male, HCV G4 since 1996, F-scan score 9, F2, Failed prior I/R, finished sof/vel/vox 8 weeks 5/16, pre-treatment VL 2 million, EOT UND, EOT+4 UND, EOT+12 UND.

Tig


Admin

Status: Offline
Posts: 7950
Date:
Permalink  
 

Thanks Canuck! Very promising news. Now if we can just see Big Pharm climb on-board and all of the regulatory agencies approve it. It's amazing how much it actually costs to provide these medications when money isn't the primary objective.



__________________

Tig

61 yo GT1A - 5 Mil - A2/F3 - (1996) Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 1-4 years!

Hep C FAQ

Signature Line Set Up/Abbreviations   Payment Assistance

 



Guru

Status: Offline
Posts: 1516
Date:
Permalink  
 

Hey Canuck,

A lot of jaw dropping information in that relatively short text ...

Time to get with the program ... get the logistics figured out, the costs down and get people treated.

At least now there is a way where not long ago we couldn't say that.

"Currently, less than 1 million people are being treated for hepatitis C worldwide, according to our analysis of exported raw materials," Hill said. "By contrast there are an estimated 2 to 4 million new infections with hepatitis C each year. So unless we increase the numbers of people treated, the epidemic of hepatitis C will continue worldwide." - by Will Offit

Thanks for another very interesting read.

 

Linux



__________________

63yy,HCV,2b,F3-A1, Sof/Riba,12wks Tx   SOT: 1/20/16, HCV-RNA 9,816,581, ALT 56, Hb 14.6

4wk: HCV-RNA <15 Detected, ALT 15, AST 17, Hb 13.6 EOT: 4/12/16, ALT 18 , Hb 12.9176a2f85d05d9c965eafe199f2ba9ba5.jpg SVR Achieved 7/8/16

 



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Sof/Vel - Current/Future pricing?

Novel HCV DAAs could be mass-produced under $90 per person

July 26, 2016

If international donors place larger orders, novel direct-acting antivirals to treat hepatitis C could be mass-produced for under $90 per person, according to data presented at AIDS 2016.

"A course of treatment to cure hepatitis C could be mass produced for under $90 per person, if we can follow the same methods of production used to treat 17 million people with HIV/AIDS using antiretrovirals," Andrew Hill, PhD, senior visiting research fellow in the pharmacology department at Liverpool University, told Infectious Disease News. "For this to happen, we need international donors or national health authorities to place large orders for treatment. We would need orders for at least 1 million courses of treatment to achieve the $90-unit price."

Andrew Hill

Novel DAAs can achieve sustained viral response rates above 90%, according to Hill and colleagues. However, the lowest price for a 12-week course of Sovaldi (sofosbuvir, Gilead Sciences) is $324 and "access" prices are available in countries only covering 50% of the worldwide epidemic, they said.

To measure how prices for novel DAAs are beginning to fall, the researchers extracted data from the first half of 2016 on the per-kilogram prices of exported active pharmaceutical ingredient (API) and exported volumes and determined per-pill API costs according to daily dosage. They estimated a cost of $0.04 per pill for formulation and excipients, $0.35 a month for packaging and a 50% profit margin.

They found that the total exports from India during this period were 10.2 tons of sofosbuvir, which is equivalent to 303,000 12-week treatment courses; 5,443 kg of Daklinza (daclatasvir Bristol-Myers Squibb), which is equivalent to 1,080,000 courses; and 240 kg of ledipasvir (Gilead Sciences), which is equivalent to 32,000 courses.

API prices decreased during this period. At the end of May 2016, the API price was $1,094/kg for sofosbuvir, $998/kg for daclatasvir, $2,441/kg for ledipasvir and between $8,900 and $11,700/kg for velpatasvir. Prices in the United States were 1,355 times higher than the target price for sofosbuvir, 4,500 times higher for daclatasvir, 984 times higher for Harvoni (ledipasvir/sofosbuvir, Gilead Sciences) and between 346 and 413 times higher for Epclusa (sofosbuvir/velpatasvir, Gilead Sciences).

Overall, 12-week treatments of sofosbuvir can be manufactured for $62, sofosbuvir plus ledipasvir for $96, daclatasvir for $14 and sofosbuvir plus velpatasvir for between $181 and $216, all of which include a 50% profit margin.

"Currently, less than 1 million people are being treated for hepatitis C worldwide, according to our analysis of exported raw materials," Hill said. "By contrast there are an estimated 2 to 4 million new infections with hepatitis C each year. So unless we increase the numbers of people treated, the epidemic of hepatitis C will continue worldwide." - by Will Offit

Reference:

Gotham D, et al. Abstract A-792-0516-01639. Presented at: AIDS 2016 Annual Meeting; July 18-22, 2016; Durban, South Africa.

 

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Moderator

Status: Offline
Posts: 861
Date:
Permalink  
 

Thanks C,  I hope I don't half to wait tell 2018 for the salvage regimen. Everything I have heard is it should be out in early 2017??  But if the trial results aren't noted untell Q1-2017 then it could very well be 2018 to get the drugs to market?  I may just do the Sof-vel and see what happens!!   RC



__________________

 M-61 (3 Treatments)( SOF-RIBA 2014)(SOF-RIBA-PEG 2016)(HCC 2016) (LIVER TRANSPLANT 8-2017)(VOSEVI-RIBA 2017) On my way to SVR.    SVR-12. 3-13-18



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

EPCLUSA and VOX

Gossipy stuff / Marketing type interview ...

GILD's plans for its HCV treatments: clear and concise

The company's EVP and CSO, Norbert Bischofberger, presented last week at a Goldman Sachs (NYSE:GS) conference. One of his comments about GILD's HCV plans was quite revealing. He said:

That is the end of the development [of HCV drugs for GILD]. I mean, there will always be some more studies that you do for a commercial product to look at different patient populations or elderly or pediatrics we're still doing that, but we actually stopped hepatitis C drug discovery about two years ago. We moved everybody in research from hepatitis C on to hepatitis B. And because we simply don't see what the additional needs there are. If you have one pill that's very safe you can treat somebody for eight or 12 weeks and you get cure rates of close to 100%, but that's a difficult thing to improve upon.

That's pretty clear, and beyond that, it looks to me as an almost direct challenge to J&J's (NYSE:JNJ) plans to enter this field (As a relevant aside, I think that JNJ should see if it buys GILD at some low price).

He also confirmed GILD's goal is to use its SOF/VEL combo (Epclusa will be the trade name) internationally for countries or regions where genotyping is not readily done, for cost and/or technical regions.

The questioner asked him to clarify the plans for GILD's three-drug HCV combo (sofosbuvir, velpatasvir and voxilaprevir = SOF/VEL plus a protease inhibitor), in this exchange:

 

 

Terence Flynn

Okay, fair enough. Separately you are conducting a Phase 3 program with a triple combo, maybe just remind us of the target profile here and then again where this drug will be positioned given what we just discussed.

Norbert W. Bischofberger

Yes, so what we're pursuing our Phase 3 studies with a triple combo in HCV is two populations, one for frontline therapy with eight weeks treatment duration in everybody without viral load cut off and the second I think that's the more important application, it is a universal salvage regimen. So you could use this drug if you have failed other direct acting antivirals you have acquired resistance mutations like in the NS5A or in the protease you could use this drug. And if of course if the Phase 3 would support that and you would then be able to achieve cure rates, high cure rates.

It appears from ClinicalTrials.gov that the Phase 3 studies could be completed by Q1 next year, thus if successful, the three-drug combo could reach the market in H1 2018.

 

GILD is pulling a Larry Bird on its competitors in HCV. It is saying that everybody else is playing for second; it's won the HCV battle and is moving on. Or to mix a sports metaphor, it's about to cross the finish line, and all the others are far in the jockey's metaphorical rear-view mirror.

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Senior Member

Status: Offline
Posts: 122
Date:
Permalink  
 

Hi Canuck, great article... Love all your research in finding all this info.  I think things will get all dialed in by 2017 for all Genotypes .  CC



__________________

F 63,  1b  1974, no cirrhosis, fibro scan 5.8 F0-F1,fibro test .37 ,V/L 702987, ALT 90, AST 75.  ABBVIE Topaz II on 10-30-14 Viekira Pak no RIBA , EOT 1-22-15 SVR, ALT 37, AST 29, 4-15-15 SVR12 - fibro test .22,  1-21-16 SVR 52 ,  1-21-17 SVR 104!



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Not about sof/vel, per say, but, IS about new daa's (in general) and GT3's. (I can't wait for the day when no GT has to do any riba regime!) smile C.

 

Article - Researchers VS Nice - Daa's VS interferon/riba for GT3's (duh!)

Fibrosis in HCV genotype 3 progresses with age

June 27, 2016

Evidence of fibrosis was common in older patients with hepatitis C virus genotype 3 infection, indicating fibrosis progresses with age and this patient population should be treated as often and with the same medications as other severe HCV patient populations, according to data presented at the British Society of Gastroenterology Annual Meeting.

According to Keeley Fairbrass, of the Digestive Disease Centre, Bradford Teaching Hospitals NHS Foundation Trust, U.K., and colleagues, The National Institute for Health and Care Excellence (NICE) previously issued a guidance that recommended only patients with moderate to severe HCV be treated. More recently, NICE advised that patients with HCV genotype 3 be treated with pegylated interferon plus ribavirin, and not direct-acting antivirals.

The researchers sought to determine the rate of fibrosis in this patient population, due to the fact the current recommended treatment indicates a longer treatment duration with lower sustained virologic response and more adverse events.

They analyzed data from a single center database to measure demographics, age of liver biopsy, fibrosis stage and SVR in patients with HCV genotype 3. Between 1998 and 2015, 477 patients underwent biopsy.

"We aimed to plot the rate of progression of fibrosis in HCV [genotype 3] patients to ensure NICE guidance isn't disadvantageous to this group," the researchers wrote.

Among those with HCV genotype 1 (n = 112; 81 men, average age 40 years; 31 women, average age 42 years), 48% achieved SVR. In the HCV genotype 2 group (n = 16; 10 men, average age 39 years; 6 women, average age 43 years), 75% achieved SVR. For HCV genotype 3 (n = 337; 194 men, average age 39 years; 143 women, average age 40 years), 68% achieved SVR. In the HCV genotype 4 group (n = 12; 10 men, average age 38 years; 2 women, average age 45 years), 42% achieved SVR.

In patients with F0 to F2 fibrosis, SVR was 80%; in patients with F3 to F4 fibrosis, SVR was 70%; and in patients with F5 to F6, SVR was 65%.

"The point prevalence of fibrosis in HCV [genotype 3] at the time of liver biopsy ...[c]onfirms that fibrosis progresses with age, but not in an exponential way and also recognizes the well-described fall in SVR with increasing fibrosis," the researchers wrote.

The researchers concluded: "Our SVR data strongly suggests that we should provide all of our HCV [genotype 3] patients with the new potent DAAs to prevent progression of disease and subsequent consequences. We urge for a change in the current guidance." - by Melinda Stevens

References:

Fairbrass K, et al. Abstract #PTH-100. Presented at: British Society of Gastroenterology Annual Meeting; June 20-23, 2016; Liverpool, U.K.

 

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

FDA OKs Epclusa, First Drug for All Major Forms of HCV

Robert Lowes

The US Food and Drug Administration (FDA) has approved the combination drug of sofosbuvir and velpatasvir (Epclusa, Gilead Sciences) for adults with chronic hepatitis C virus (HCV) infection, the first one to treat all six major genotypes of the infection, the agency announced today.

The new drug's broad coverage could make it a one-size-fits-all therapy suitable for primary care. Gilead Sciences President and CEO John Gilliland said in a news release thatsofosbuvir/velpatasvir could eliminate the need for genotype testing, "which can be a barrier to treatment in certain resource-constrained settings."

"This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C," Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

Sofosbuvir won FDA clearance in 2013, while velpatasvir is a new drug. The combination drug, a fixed-dose tablet, is indicated for patients with chronic HCV infection whether or not they have cirrhosis. However, patients with moderate to severe cirrhosis should use the new drug together with ribavirin.

Sofosbuvir/velpatasvir treats HCV genotypes 1 through 6, with genotype 1 accounting for 75% of cases in the United States.

Like many HCV drugs of recent vintage, sofosbuvir/velpatasvir does not require concomitant use of interferon, known for its harsh adverse effects. And more important, it is another HCV drug that achieves a cure rate topping 90% with just a 12-week regimen.

Last month the European Medicines Agency recommended approval of sofosbuvir/velpatasvir in the European Union.

The wholesale price of the new drug is $74,760 for a 12-week regimen, Gilead Sciences spokesperson Cara Miller told Medscape Medical News. That price is considerably less than the company's wholesale prices of $84,000 and $94,500 for Sovaldi and Harvoni, respectively, its other HCV drugs containing sofosbuvir.

"Gilead believes the pricing of Epclusa will facilitate access for the US population with the greatest unmet medical need patients with genotypes 2 and 3 who previously required more complex and costly multitablet regimens," Miller said in an email. "For genotype 3 patients in particular, the cost of Epclusa will be half the cost of the most commonly used regimen (sofosbuvir plus daclatasvir)."

Avoid Prescribing Alongside Amiodarone

The FDA evaluated four clinical trials to establish that sofosbuvir/velpatasvir is safe and effective. In three trials involving 1558 patients with HCV who had no cirrhosis or only mild cirrhosis, 95% to 99% of patients taking the new drug had no detectable virus in their bloodstream after 12 weeks of treatment. In the fourth trial, 87 patients with HCV and moderate to severe cirrhosis received sofosbuvir/velpatasvir along with ribavirin, and there was no detectable virus in the bloodstream in 94%.

Headache and fatigue were the most common adverse events observed in the clinical trials.

The drug's label warns against administering sofosbuvir/velpatasvir with amiodarone because reports of symptomatic bradycardia and pacemaker interventions have surfaced for patients who have used sofosbuvir with the antiarrhythmic agent. The label also warns against using sofosbuvir/velpatasvir with certain other drugs that may reduce its bloodstream amount and efficacy.

 

More information about the new HCV drug is available on the FDA website.



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Tig's links - more good data on sof/vel/vox.

 

Sov/Vel/Vox Triple

Gilead Triple

NS3/4A Protease Inhibitor GS-9857



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Senior Member

Status: Offline
Posts: 362
Date:
Permalink  
 

Presenting the world's leading expert in sof/vel/vox....drum roll, please....Canuck, boxing out of the right corner, wearing red and the maple leaf, representing Canada, weighing in at, well, not very much really, but she is the the world's best pound-for-pounder and the undefeated IBF world champion with a record of super-quick knockouts of the dragon.



__________________

44 y.o. male, HCV G4 since 1996, F-scan score 9, F2, Failed prior I/R, finished sof/vel/vox 8 weeks 5/16, pre-treatment VL 2 million, EOT UND, EOT+4 UND, EOT+12 UND.



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Another author, re-write/compilation/look at old and new(er) stats on sof/vel/vox, but a dif. twist noted in the potential exploration in use of "RG-101". This RG-101 seemed to be a slow in coming/developing drug that was talked about quite some time ago on this site (between Mallani and Matt Chris mostly, I think?). I just found it kinda interesting that I have now seen the potential use of RG-101 being mentioned again, twice recently, once here: 

Reuters Health Information

New Combination Therapy May Be Effective Against Chronic HCV Infection

By Will Boggs MD

June 14, 2016

NEW YORK (Reuters Health) - The new NS3/4A protease inhibitor GS-9857, in combination with sofosbuvir and velpatasvir (SOF/VEL), produces sustained viral response in most patients with hepatitis C virus (HCV) genotype 1 or 3 infections, according to a phase 2 trial from Gilead Sciences.

Various combinations of direct-acting antiviral agents (DAAs) provide sustained virologic responses in most patients infected with HCV, but there are ongoing efforts to optimize and shorten regimens.

Dr. Edward J. Gane from Auckland City Hospital in New Zealand and colleagues evaluated the efficacy and safety of short-duration regimens (four, six, or eight weeks) of SOF/VEL plus GS-9857 in a broad range of patients with genotype 1 (n=120) and 3 (n=41) HCV infections, including 63 treatment-naïve patients and 98 previously-treated patients.

Sustained viral response at 12 weeks (SVR12) was achieved by 27% of treatment-naïve patients with genotype 1 infection without cirrhosis after four weeks of treatment and by 93% after six, the team reports in Gastroenterology, online May 27.

SVR12 was 87% among treatment-naïve patients with cirrhosis after six weeks of treatment, while it was 67% among DAA-experienced patients with and without cirrhosis. In patients who had received other previous treatment and did or did not have cirrhosis, SVR12 with eight weeks of therapy ranged from 89% to 100%.

Among patients with genotype 3 infection, SVR12 was achieved by 83% of treatment-naïve patients with cirrhosis after six weeks of treatment and by 100% of previously treated patients with or without cirrhosis after eight weeks of treatment.

Of the 30 patients who did not achieve SVR12, 28 had virologic relapse after completing treatment, one withdrew consent four weeks after the treatment ended (at which time the patient had undetectable HCV RNA), and one never attained HCV RNA below 15 IU/mL on treatment.

Relapse rates were 73% among patients who received only four weeks of treatment, 19% among those who received six weeks of treatment, and 4% among those who received eight weeks of treatment.

SVR12 rates were also high among patients who had resistance-associated substitutions at baseline (84%-86%, depending on the threshold), and no treatment-emergent resistance-associated substitutions were detected in 26 of 28 patients who relapsed.

Common adverse events included headache, nausea, fatigue, and diarrhea, most of which were mild in severity. No patient discontinued treatment due to an adverse event.

 

"These results suggest that 8 weeks is the threshold of treatment duration with combination DAAs for the easier-to-treat patient population, not 4 or 6 weeks as suggested by recent viral kinetic models," the researchers note. "Future attempts to shorten duration of DAA regimens to less than 8 weeks will probably require the addition of a host-targeting agent such as RG-101, an miR-122 antagonist, which has been shown to do so in the interim results of an ongoing phase 2 study."

"SOF/VEL/GS-9857 is now coformulated as a single tablet which is being evaluated in the larger Phase III program, which includes different patient populations, including DAA-experienced patients," they add. "This group of DAA-experienced patients is growing and currently represents an unmet medical need."

Dr. Assy Nimer from Ziv Medical Center in Haifa, Israel, who has studied various aspects of HCV infection and its treatment, told Reuters Health by email, "The most interesting or surprising results is the low rate of SVR at week 4 in naïve HCV genotype 1 patients without cirrhosis, indicating that the combination of three potent DAA is not effective for 4 weeks but is highly effective for 8 weeks of treatment."

 

"The best treatment duration of the new DAA combination would be between 8 and 12 weeks," he concluded, adding that "this type of new medications will likely be effective in minimizing resistance-associated variants (RAV), which persist for years."

Gilead Sciences supported the trial, employed several authors, and had various relationships with the rest, including Dr. Gane.

Dr. Gane did not respond to a request for comments.

SOURCE: http://bit.ly/1UaduVG

 

Gastroenterology 2016.

 

 



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

Tig posted this link:

Re: Newly named sof/vel - "EPCLUSA", so dragged it over to this thread. Did not mention GS-9857 (VOX) tho.

 Healio HCV Next

 

Loopylisa posted this news release:

Re: Newly named sof/vel - "EPCLUSA", so dragged it over to this thread (even tho "Eplusa" will not BE JUST for GT3's)!!

Does make mention of GS-9857 (VOX)

http://finance.yahoo.com/news/gileads-gild-hcv-drug-epclusa-140402864.html



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)



Guru

Status: Offline
Posts: 2394
Date:
Permalink  
 

So, still no "new" news on GS-9857!!

I stumbled across gs-9857's "new" name today, by accident, looking for any new sov/vel/gs-9857 trials, where I saw gs-9857 fondly (and officially) referred to as "VOX".

Tig did find a molecular pic of "VOX" today (good'un for avatar use)!

But after a search (you knew I would) I really could find no good revealing new data about this mysterious NS3/4A protease inhibitor "VOX" (formerly gs-9857)

I did find the reference as to when it's name (VOXILAPREVIR) was first registered - Nov. 2, 2014 (bor-ing), and the last date the name might have been changed - Jan. 10, 2016 (yawn), AND that it has a close (Latin) "international" name of VOXILAPREVIRUM", but that is NOT really the kind of data I wished for.

The closest thing I could find to "new" news was from a May 23rd conference (about Gilead company performance) where the EVP of Gilead R&D spoke of all their drugs, and of sof/vel/vox, and made mention of the newness of the name voxilaprevir (to him!) - apparently he had only been getting his mouth used to using the name for about 2 weeks! The EVP also made mention of the "pan-ness" of sof/vel (pan enough for all GT's), and proudly made mention (yet again) of the fast-tracking consideration sof/vel has received, with a decision date on same supposedly pending Jun 28.

Of the recent sof/vel/vox trials, even the "primary" result due date, is not going to be until Dec of 2016!!

So, for now, all one can do (when they ponder just what kind of NS3/4A protease inhibitor IS this that I am ingesting anyway), is to re-read the Gilead trial handout that specifies possible sides. Or, try to compare VOX to one of the many other and older types of NS3/4A protease inhibitors!!

Vox being described as an "aco-molar" inhibitor, doesn't tell me much, nor does it's "appearance" to perform better, as a good pan PI, provide me much comfort! "Sounds" good (in theory) the suspected lessening of RAV probs., but I can't wait until they actually publish something new, and something from these recent trials, on vox!! (and on vel too!) Sigh, hmm C.



__________________

HCV/HBV 1973. HBV resolved. HCV undiagnosed to 2015. 62 y.o. F. Canada.

GT3a, Fibroscan F3/12 kPa - F4/12.6 kPa, VL log 7.01 (10,182,417), steatosis, high iron load.

SOF/VEL with/without GS-9857 trial - NCT02639338.

SOT March 10 - EOT May 5, 2016 - SOF/VEL/VOX 8 week trial.

 

(SEE UPDATES IN BIO)

«First  <  1 2 3  >  Last»  | Page of 3  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.